Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFFITOPE PD01A in Parkinson's Disease with GBA Mutation
NCT02758730Phase 1Withdrawn
- Sponsor
- AFFiRiS
- Primary completion
- Oct 2017
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in Parkinson's disease (PD) comparing AFFITOPE PD01A with Placebo (2 arms). Primary endpoints: Number of patients who withdraw due to Adverse Events at 52 weeks, Occurrence of any Serious Adverse Event at 52 weeks and 4 more. Status: withdrawn.
02
Drugs
AFFITOPE PD03A
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02758730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02758730.